BUREAU-VERITAS
8.11.2021 18:55:08 CET | Business Wire | Press release
Envision Digital International Pte Ltd (“Envision Digital”), a Singapore-headquartered global Artificial Intelligence of Things (AIoT) technology leader for net zero, and Bureau Veritas , a world leader in testing, inspection and certification, will jointly develop net zero technology solutions helping businesses, organisations and governments around the world drive climate action, make meaningful progress on their net zero commitments, and do so in a standardized, certifiable, and verifiable manner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108005906/en/
Lei Zhang, Founder and CEO of Envision Group, commented:
“ “Through strategic partnership with Bureau Veritas, our best practices of digital solution will help more companies around the world accelerate their net zero transition. ”
Didier Michaud-Daniel, CEO of Bureau Veritas, added:
“Our role as an independent third party is essential to shape trust between economic players. Through our BV Green Line of services and solutions, we support our 400,000 clients to be more efficient, more methodical and more trustworthy in their journey towards more sustainable business and a more sustainable world. Together with Envision Digital, we will provide organizations with end-to-end solutions combining our respective strengths focused on achieving clients’ net-zero goals, and thus contribute to a positive impact on people and the planet. ”
While the number of organizations making net zero pledges has increased, there is also growing concern about the credibility of commitments that lean heavily on carbon offsets. In addition, increasing calls for greater transparency and accountability in emissions reporting have added another layer of difficulty on an organization’s road to net zero. The combination of Envision Digital’s AIoT technology and Bureau Veritas’ unrivalled expertise in sustainability certification and auditing processes will enable organisations to better align with internationally recognized carbon-neutral standards.
About Bureau Veritas
Bureau Veritas is a world leader in laboratory testing, inspection and certification services. Created in 1828, the Group has more than 78,000 employees located in more than 1,600 offices and laboratories around the globe. Bureau Veritas helps its 400,000 clients improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the Next 20 index.
Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com
, and follow us on Twitter
(@bureauveritas) and LinkedIn
.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com
About Envision Digital
Envision Digital is committed to becoming the world’s leading net zero technology partner for enterprises, governments, and cities alike. Its world-class AIoT technology helps governments and companies across the world accelerate progress toward a net zero future and improve their citizens’ quality of life. Having established itself as a leading solutions provider for intelligent renewable energy generation, consumption efficiency and smart and flexible storage, Envision Digital has extended its capabilities beyond energy to enable and optimise applications – notably in smart renewables, city infrastructure and carbon management solutions.
EnOS™, Envision Digital’s proprietary AIoT operating system, connects and manages more than 110 million smart devices and 360 gigawatts of energy assets globally and with Envision Ark, it has earned Envision Group a place on Fortune’s 2021 Change The World list. Envision Digital’s growing ecosystem of more than 360 customers and partners spans 10 industries and includes Accenture, Amazon Web Services, GovTech Singapore, Keppel Corporation, Microsoft, Nissan, PTT, Solarvest, Total and ST Engineering. The company has close to 800 employees and 12 offices across China, France, Japan, Germany, Norway, the Netherlands, the United Kingdom, and the United States, with headquarters in Singapore.
For more information, please visit www.envision-digital.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005906/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom